{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T17:37:08Z","timestamp":1792949828475,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtha.2025.09.041","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:35:23Z","timestamp":1761550523000},"page":"747-765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8970-9473","authenticated-orcid":false,"given":"Caroline M.A.","family":"Mussert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-0061","authenticated-orcid":false,"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-8586","authenticated-orcid":false,"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-6312","authenticated-orcid":false,"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-7669","authenticated-orcid":false,"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-2089","authenticated-orcid":false,"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-5020","authenticated-orcid":false,"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-2621","authenticated-orcid":false,"given":"Jan","family":"Voorberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn F.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-1958","authenticated-orcid":false,"given":"Radoslaw","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7808-3462","authenticated-orcid":false,"given":"Paul","family":"Batty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-0719","authenticated-orcid":false,"given":"Ilaria","family":"Cutica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-1371","authenticated-orcid":false,"given":"Frank W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.09.041_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.09.041_bib2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.041_bib3","first-page":"223","article-title":"Emicizumab for the treatment of haemophilia A: a narrative review","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2025.09.041_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.09.041_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.041_bib6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.041_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102476","article-title":"Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study","volume":"8","author":"Tran","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib9","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/a-1424-7900","article-title":"Nonfactor therapies: new approaches to prophylactic treatment of haemophilia","volume":"41","author":"Chowdary","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2025.09.041_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtha.2025.09.041_bib12","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.09.041_bib13","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jtha.2023.08.032","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1","volume":"21","author":"O\u2019Mahony","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/hae.14977","article-title":"Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: results from the phase III HOPE-B trial 2 years after gene therapy","volume":"30","author":"Itzler","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2025.09.041_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jvh.13919","article-title":"Hepatitis after gene therapy, what are the possible causes?","volume":"31","author":"Maina","year":"2024","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jtha.2025.09.041_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial","volume":"8","author":"Leavitt","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.041_bib20","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1111\/jth.15023","article-title":"Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: communication from the SSC of the ISTH","volume":"18","author":"Konkle","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/hae.14981","article-title":"EAHAD haemophilia gene therapy clinical outcome database (EAHAD-GTD)","volume":"30","author":"Miesbach","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib22","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jtha.2023.12.039","article-title":"Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy","volume":"22","author":"Miesbach","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib27","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/hae.14420","article-title":"Delivery of AAV-based gene therapy through haemophilia centres\u2014a need for re-evaluation of infrastructure and comprehensive care: a Joint publication of EAHAD and EHC","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib29","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/hae.14887","article-title":"Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy","volume":"29","author":"Boban","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/hae.14709","article-title":"Laying the foundations for gene therapy in Italy for patients with haemophilia A: a Delphi consensus study","volume":"29","author":"Castaman","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib31","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.jtha.2024.07.029","article-title":"Gene therapy for people with Haemophilia B: a proposed care delivery model in Italy","volume":"22","author":"Castaman","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/hae.15125","article-title":"UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults","volume":"31","author":"Chowdary","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib33","first-page":"196","volume":"43","author":"Miesbach","year":"2023"},{"key":"10.1016\/j.jtha.2025.09.041_bib34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/hae.14309","article-title":"Evolution of haemophilia integrated care in the era of gene therapy: treatment centre\u2019s readiness in United States and EU","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/hae.14908","article-title":"Perspectives and perception of haemophilia gene therapy by French patients","volume":"30","author":"Pietu","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib37","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/hae.14867","article-title":"Delivery of gene therapy in haemophilia treatment centres in the United States: practical aspects of preparedness and implementation","volume":"29","author":"Pipe","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109180","article-title":"Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: a survey-based study","volume":"244","author":"Villas","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.041_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/bmjebm-2022-112168","article-title":"Metro Mapping: development of an innovative methodology to co-design care paths to support shared decision making in oncology","volume":"28","author":"Stiggelbout","year":"2023","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.jtha.2025.09.041_bib40","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.041_bib41","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2018-99-119616","article-title":"Activity of a FIX-Padua transgene product in commonly used FIX:C one-stage and chromogenic assay systems following PF-06838435 (SPK-9001) gene delivery","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.041_bib43","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/hae.15100","article-title":"Development of the World Federation of Hemophilia shared decision-making tool","volume":"30","author":"Coffin","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib44","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2147\/PPA.S355627","article-title":"The hemophilia gene therapy patient journey: questions and answers for shared decision-making","volume":"16","author":"Wang","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2025.09.041_bib45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/hae.14985","article-title":"Administration of gene therapy for haemophilia\u2014the hub and spoke model and its regional differences and challenges","volume":"30","author":"Miesbach","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib46","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/jth.15281","article-title":"Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua","volume":"19","author":"Robinson","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib47","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.041_bib48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.13643","article-title":"Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme","volume":"25","author":"van Moort","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.041_bib49","article-title":"Adeno-associated virus-based gene therapy for haemophilia\u2014addressing the gaps","volume":"9","author":"Miesbach","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.041_bib50","author":"Miesbach"},{"key":"10.1016\/j.jtha.2025.09.041_bib51","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/gt.2017.95","article-title":"Strategy to detect pre-existing immunity to AAV gene therapy","volume":"24","author":"Falese","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2025.09.041_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.omtm.2021.05.012","article-title":"Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-\u03b3 ELISpot method","volume":"22","author":"Patton","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2025.09.041_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221104591","article-title":"Gene therapy in haemophilia: literature review and regional perspectives for Turkey","volume":"13","author":"Kavakl\u0131","year":"2022","journal-title":"Ther Adv Hematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:21:17Z","timestamp":1778224877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625006695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1538783625006695"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.041","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}